Trevena

Update in progress

TRVN (OTC Markets OTCPK)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Trevena, Inc. is a biopharmaceutical company focused on developing and commercializing medicines for central nervous system disorders. Its lead programs include OLINVYK (Oliceridine) injection, a G protein–biased mu-opioid receptor ligand for moderate-to-severe acute pain; TRV734, a MOR-biased small molecule that has completed Phase I trials for acute and chronic pain; and TRV045, a novel S1P modulator for chronic pain. Founded in 2007, based in Chesterbrook, Pennsylvania.

Company score

Sentiment: 0.22; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.14; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.09; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.06; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.14; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive